Current appointments: Senior Researcher, Director of research at INSERM, France
1990 B.SC (Hons), first calss, (Paris VII University)
1995 Ph.D. (Paris VII University)
1995-1998 Postdoctoral Fellow (Sandoz contract). Paris VI Lariboisière
1999-2003 Research associate, University of Toronto, Dr. JRG Challis
2003-2005 Researcher: Young investigator program INSERM EMI105
2005 Researcher: INSERM Institute
2010 Habilitation to supervise research programs
2005 Director of research at INSERM Institute
Honors and Awards
1991-95 National PhD Science Scholarship
1992-93 Society of Nephrology Prize
1996-98 Postdoctoral Fellow from Sandoz Company
1999-2003 MRC Grant for the study of Preterm labor
1999-2000 Award for best post-doctoral fellow of the year
2001 New investigator Prize “International Trophoblast meeting”
2003-2005 French Foundation for Medical Research
2003-2006 Young Investigator contract with INSERM, France
2005-2006 PNR grant : Programme en endocrinologie et reproduction
2007-2012 Recipient of Interface contract Grenoble Hospital
2008-2010 Recipient of regional Grant “Rhône Alpes”
2009-2012 Recipient of DHOS-INSERM Grant: A clinical study
2014-Present French investigator of the French-Moroccan cooperation
2015-Present Principal investigator “Auvergne-Rhône-Alpes” partnership
2015-Present Recipient of project Ligue contre le cancer
2015-Present Recipient of project CLARA Oncostarter
Dr Alfaidy’ research has contributed in a fundamental manner to advances in the understanding of pregnancies pathologies that are associated with abnormal function at the fetomaternal barrier. Her postdoctoral studies have uncovered some of the key roles of steroids and prostaglandins in the birth process and have elucidated some of the current concepts of the autocrine and paracrine regulations in women. Since March 2003 Dr. Alfaidy’ research has been focused on the understanding of the mechanisms of the development of Preeclampsia, the most common cause of retarded fetal development. Dr. Alfaidy’s actual research is focused on the study of a new family of proteins, the prokineticin, recently identified as pro-angiogenic and proinflammatory, in relation to pregnancy pathologies. Her recent work also identified the prokineticin1 as an angiogenic protein associated with placenta tumor development and progression. Ongoing studies in her group aim at developing therapeutic molecules and antibodies to interfere with prokineticin-1 signaling pathway.